AFM
VVOS icon

Anson Funds Management’s Vivos Therapeutics VVOS Stock Holding History

Anson Funds Management’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-242,583
Closed -$1.04M – 185
2024
Q4 		$1.04M Buy
+242,583
New +$809K 0.11% 88
2022
Q1 		– Sell
-4,892
Closed -$275K – 433
2021
Q4 		$275K Buy
+4,892
New +$394K 0.03% 278

Other funds holding VVOS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EL
EWA LLC Pittsbugh, Pennsylvania $548M AUM 35.14% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM

Anson Funds Management's VVOS Position: Q1 2025 in Review

Anson Funds Management sold out of Vivos Therapeutics (VVOS) in Q1 2025, closing a stake of 242,583 shares — an estimated $1.04M sold.

Anson Funds Management first reported a position in VVOS in Q4 2021 and held it in 2 quarters. The position peaked at $1.04M in Q4 2024. 20 funds tracked by Wall St. Rank hold VVOS as of Q1 2025.

  • Anson Funds Management reported no remaining Vivos Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Anson Funds Management sold 242,583 Vivos Therapeutics shares in Q1 2025, an estimated $1.04M.
  • Anson Funds Management first reported a position in Vivos Therapeutics in Q4 2021 and held it in 2 quarters.
  • Anson Funds Management's Vivos Therapeutics position peaked at $1.04M in Q4 2024.
  • 20 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q1 2025.

Based on Anson Funds Management's 13F filing for Q1 2025, filed 14 May 2025.